CDH5 and breast cancer: The data from ELISAs suggests that CDH5 and CDH5:HPA ratio values may offer a lead time in the diagnosis of metastatic disease, as the average time to metastasis (from diagnosis) in this cohort of patients was 32.0 months (±3 months) post primary breast cancer diagnosis.